Skip to main content

Advertisement

SpringerLink
Log in

Lipodystrophy Severity Does Not Contribute to HAART Nonadherence

  • Original Article
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Lipodystrophy severity among 77 people living with HIV/AIDS (PHA) with body fat redistribution was not related to antiretroviral adherence including doses missed during the previous month, categorical rating of maximal adherence, and the PMAQ7 adherence behavior scale. Two thirds of the sample reported submaximal adherence, 19% missing more than two doses, but adherence behavior ratings reflected good overall adherence. Overall symptom burden, convenience of regimen schedule and remembering to organize and take antiretroviral doses, but not regimen adaptation or treatment support, were associated with adherence. Remembering was most strongly related to adherence indicators, retaining statistical significance in adjusted multivariate regression analyses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Ammassari, A., Antinori, A., Cozzi-Lepri, A., Trotta, M. P., Nasti, G., Ridolfo, A. L., Mazzotta, F., Wu, A. W., D'Arminio Monforte, A., and Galli, M. (2002a). Relationship between HAART adherence and adipose tissue alterations. Journal of Acquired Immune Deficiency Syndromes, 31, S140–S144.

    Google Scholar 

  • Ammassari, A., Murri, R., Pezzotti, P., Trotta, M. P., Ravasio, L., De Longis, P., Lo Caputo, S., Narciso, P., Pauluzzi, S., Carosi, G., Nappa, S., Piano, P., Izzo, C. M., Lichtner, M., Rezza, G., Monforte, A., Ippolito, G., D'Arminio Moroni, M., Wu, A. W., and Antinori, A. (2001). Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. Journal of Acquired Immune Deficiency Syndromes, 28, 445–449.

    CAS  Google Scholar 

  • Ammassari, A., Trotta, M. P., Murri, R., Castelli, F., Narciso, P., Noto, P., Vecchiet, J., D'Arminio Monforte, A., Wu, A. W., and Antinori, A. (2002b). Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. Journal of Acquired Immune Deficiency Syndromes, 31, S123–S127.

    PubMed  Google Scholar 

  • Bartlett, J. A. (2002). Addressing the challenges of adherence. Journal of Acquired Immune Deficiency Syndromes, 29, S2–S10.

    PubMed  Google Scholar 

  • Bassetti, S., Battegay, M., Furrer, H., Rickenback, M., Flepp, M., Kaiser, L., Telenti, A., Vernazza, P. L., Bernasconi, E., and Sudre, P. (1999). Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Journal of Acquired Immune Deficiency Syndromes, 21, 114–119.

    CAS  Google Scholar 

  • Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D., and Cooper, D. A. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12, F51–F58.

    Article  PubMed  CAS  Google Scholar 

  • Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G., Chisholm, D., and Cooper, D. (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: A cohort study. Lancet, 353, 2093–2099.

    Article  CAS  Google Scholar 

  • Collins, E. J., Wagner, C. A., and Walmsley, S. L. (2000). Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader, 10, 546–550.

    CAS  Google Scholar 

  • DeMasi, R. A., Graham, N. M., Tolson, J. M., Pham, S. V., Capuano, G. A., Fisher, R. L., Shaefer, M. S., Pakes, G. E., Sawyerr, G. A., and Eron, J. J. (2001). Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. Advances in Therapy, 18, 163–173.

    Article  CAS  Google Scholar 

  • Duran, S., Saves, M., Spire, B., Cailleton, V., Sobel, A., Carrieri, P., Salmon, D., Moatti, J. P., and Leport, C. (2001a). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS, 15, 2441–2444.

    Article  CAS  Google Scholar 

  • Duran, S., Spire, B., Raffi, F., Walter, V., Bouhour, D., Journot, V., Cailleton, V., Leport, C., and Moatti, J. P. (2001b). Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials, 2, 38–45.

    Article  CAS  Google Scholar 

  • Ferguson, T. F., Stewart, K. E., Funkhouser, E., Tolson, J., Westfall, A. O., and Saag, M. S. (2002). Patient-perceived barriers to antiretroviral adherence: Associations with race. AIDS Care, 14, 607–617.

    Article  PubMed  CAS  Google Scholar 

  • Fong, O. W., Ho, C. F., Fung, L. Y., Lee, F. K., Tse, W. H., Yuen, C. Y., Sin, K. P., and Wong, K. H. (2003). Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Medicine, 4, 133–138.

    Article  PubMed  CAS  Google Scholar 

  • Gifford, A. L., Bormann, J. E., Shively, M. J., Wright, B. C., Richman, D. D., and Bozzette, S. A. (2000). Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes, 23, 386–395.

    PubMed  CAS  Google Scholar 

  • Guaraldi, G., Murri, R., Orlando, G., Orlandi, E., Sterrantino, G., Borderi, M., Grosso, C., Cattelan, M. A., Nardini, G., Beghetto, B., Antinori, A., Esposito, R., and Wu, A. W. (2003). Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clinical Trials, 4, 99–106.

    Article  Google Scholar 

  • Heath, K. V., Hogg, R. S., Chan, K. J., Harris, M., Montessori, V., O'Shaugnessy, M. V., and Montaner, J. S. (2001). Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS, 15, 231–239.

    Article  PubMed  CAS  Google Scholar 

  • Jhingran, P., Tolson, J., Scott-Lennox, J., Jordan, J., and Pham, S. (1997). Development and content validation of an HIV-specific Patient Medication Adherence Questionnaire (PMAQ). Paper presented at the 37th Interscience Conference on Anti-Microbrial Agents Chemotherapy, Toronto, Canada.

  • Justice, A. C., Rabeneck, L., Hays, R. D., Wu, A. W., and Bozzette, S. A. (1999). Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: A comparison with self-reported symptoms. Journal of Acquired Immune Deficiency Syndromes, 21, 126–133.

    CAS  Google Scholar 

  • McCarron, B., Pithie, C., and Mathers, L. (1998). Adherence to anti-retroviral therapy in Glasgow HIV patients. AIDS, 12(Suppl 4), S62. Abstract P181.

    Google Scholar 

  • Paton, N. I., Earnest, A., Ng, Y. M., Karim, F., and Aboulhab, J. (2002). Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: Prevalence, associated factors and psychological impact. Clinical Infectious Diseases, 35, 1244–1249.

    Article  Google Scholar 

  • Shafer, R. W., and Vuitton, D. A. (1999). Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomedicine and Pharmacotherapy, 53, 73–86.

    Article  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS

The study investigators thank the Canadian Foundation for AIDS Research (CANFAR) for financial support for this project.

Author information

Authors and Affiliations

  1. Immunodeficiency Clinic, Toronto General Hospital, Toronto, Canada

    Evan J. Collins, Robert W. Burgoyne, Susan E. Abbey, Margaret L. Nur & Sharon L. Walmsley

  2. Department of Psychiatry, University of Toronto, Toronto, Canada

    Evan J. Collins, Robert W. Burgoyne, Susan E. Abbey & Mark H. Halman

  3. Primary Care Physician, Toronto, Canada

    Cheryl A. Wagner

  4. St. Michael's Hospital, Toronto, Canada

    Mark H. Halman

  5. Department of Medicine, University of Toronto, Toronto, Canada

    Sharon L. Walmsley

  6. Immunodeficiency Clinic, Toronto General Hospital, 200 Elizabeth St., 13N-1316, Toronto, Ontario, M5G 2C4, Canada

    Robert W. Burgoyne

Authors
  1. Evan J. Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert W. Burgoyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheryl A. Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susan E. Abbey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark H. Halman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Margaret L. Nur
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sharon L. Walmsley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert W. Burgoyne.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Collins, E.J., Burgoyne, R.W., Wagner, C.A. et al. Lipodystrophy Severity Does Not Contribute to HAART Nonadherence. AIDS Behav 10, 273–277 (2006). https://doi.org/10.1007/s10461-005-9048-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-005-9048-4

KEY WORDS:

Search

Navigation